HeLa nuclei incubated in E/X extracts underwent chromatin condensation in two stages: condensation against the nuclear rim was followed by the formation of discrete apoptotic bodies (Figure 1b) . The rim-condensation also occurred when caspase activity was inhibited with the peptide-fluoromethylketone inhibitor DEVD-fmk ( Figure 1c ) [6] . A similar phenotype was observed when nuclei were preincubated with the highly specific Topo II inhibitors ICRF-159, ICRF-187 or etoposide (VP16) for 30 minutes before addition of E/X extracts (Figure 1d-f) . Simultaneous inhibition of caspase and Topo II activity completely abolished apoptotic chromatin condensation (Figure 1d′-f′) . This was not simply a kinetic effect, as nuclei retained this normal appearance for at least 6 hours at 37°C (data not shown). This inhibition of apoptotic chromatin condensation was unlikely to arise from global changes in the accessibility of chromatin to condensation factors, as simultaneous inhibition of caspases and Topo IIα had no effect on the ability of CAD nuclease to cleave nuclear DNA into an oligonucleosomal ladder ( Figure 2e ). These experiments provide the first evidence that Topo IIα has a role in chromatin condensation during apoptosis.
The abolition of apoptotic chromatin condensation following simultaneous inhibition of Topo IIα and caspases was seen with three different Topo II inhibitors, suggesting that the effect is due to the action of the drugs on Topo IIα. In a further control, apoptotic chromatin condensation was restored when highly purified human Topo IIα [10] (Figure 2d ) was added to nuclei in E/X extract in the presence of Topo II and caspase inhibitors (Figure 1d′′ -f′′). This rescue was abrogated when the purified Topo IIα was pretreated with monospecific anti-Topo IIα antibodies (Figure 2b , and data not shown). Topo IIα alone had no effect on the morphology of nuclei in buffer after 2 hours (Figure 2a) . Finally, simultaneous inhibition of Topo I and caspases had no effect on chromatin condensation induced by E/X extracts ( Figure 2c ). These controls strongly support the conclusion that both Topo IIα and caspases act in pathways that promote apoptotic chromatin condensation. The rescue by purified Topo IIα in the presence of inhibitors raises the possibility that Topo IIα could be functioning in a non-enzymatic role, either as a structural or targeting factor, as has been proposed for its role in mitotic chromosome condensation [11] .
Simultaneous inhibition of caspases and CAD (by addition of the CAD-inhibitory chaperone ICAD-L) also blocked chromatin condensation in E/X extracts ( Figure 1h ). This confirmed our previous results suggesting that CAD and caspases act in parallel pathways of apoptotic chromatin condensation [6] . Surprisingly, inhibition of chromatin condensation could be reversed upon addition of purified human Topo IIα (Figure 1i ), suggesting that Topo IIα acts downstream of CAD or promotes condensation in a pathway parallel to the CAD pathway. It was also possible, however, that the added Topo IIα might interfere with the interaction between CAD and the exogenous ICAD added in these reactions as a CAD inhibitor.
Physical and functional interactions between Topo IIα and CAD were readily detected both in vitro and in cell extracts. Purified Topo IIα bound quantitatively to GST-CAD on glutathione-sepharose, but not to GST alone, GST-ICAD-L, GST-BubR1, GST-AIRK2, or GST-β tubulin (data not shown), or sepharose alone ( Figure 3a) . As a control, purified poly(ADP-ribose) polymerase (PARP) added to the mix did not bind to any protein (Figure 3a) . Similar Topo IIα binding was also observed with Intein-CAD (data not shown).
To confirm that Topo IIα can bind CAD in cell extracts, we made stable sublines of chicken MSB-1 cells expressing green fluorescent protein (GFP) fused to histidine (His) and haemagglutinin (HA) tags (His-HA-GFP) or very low levels of His-HA-CAD. The expressed CAD was immunoprecipitated from lysates using anti-HA antibody. These immunoprecipitates reproducibly contained Topo IIα, which was not seen in immunoprecipitates of the much more highly expressed control protein, His-HA-GFP (Figure 3b ). This shows that CAD can interact with Topo IIα in cell extracts. It is not surprising that only a fraction of Topo IIα was bound to CAD, as Topo IIα is abundant in MSB-1 cells, and is presumably present in vast excess over CAD.
The interaction between Topo IIα and CAD appears to be functionally significant. In a quantitative assay for DNA decatenation, purified GST-CAD, either on its own or as a complex with His-ICAD-L, stimulated the decatenation activity of Topo IIα two to threefold, whereas buffer, GST or GST-ICAD-L had no effect ( Figure 3c ). Under these conditions CAD is enzymatically inactive, and does not interfere with the Topo II assay (which measures the release of intact minicircles from kinetoplast networks, see Supplementary material). In other experiments, we could not detect an effect of Topo IIα inhibition or addition on CAD activity against nuclear chromatin ( Figure 2e , and data not shown).
It is widely accepted that Topo IIα is nuclear [9] , and that CAD must be nuclear during apoptotic execution [4] . The localization of CAD in non-apoptotic cells has, however, been more controversial. DFF [3] , and then CAD/ICAD [4] were first identified in cytoplasmic extracts. The first evidence that the CAD/ICAD complex might be nuclear was the observation that exogenous ICAD expressed in a variety of cell types was nuclear [6, 8] . Also, our subcellular fractionation experiments confirmed that endogenous ICAD is predominantly nuclear [6] . Consistent with this, we have identified an autonomous nuclear localization sequence at the carboxyl terminus of ICAD-L [12] . Here we address the localization of the CAD nuclease itself.
GFP-CAD is exclusively nuclear when expressed at low to moderate levels in cultured cells ( Figure 4a , panel 2; see also [12] ), and is distributed throughout the nucleus in a micropunctate pattern that largely follows the DNA distribution. Endogenous Topo IIα is similarly distributed in interphase cell nuclei (Figure 4a, panel 3) , and in a merged image (Figure 4a, panel 4) , the CAD and Topo IIα signals superimpose as a yellow signal distributed throughout the nucleus. To confirm the nuclear localization of endogenous CAD, we used a rabbit antiserum to cloned murine CAD in subcellular fractionation experiments (Figure 4b) . A substantial portion of the CAD is revealed in the nuclear fraction. Although it is possible that some CAD is normally resident in the cytoplasm, our results show that much of this protein is nuclear, and would therefore be available to interact with Topo IIα.
Our results are consistent with models in which CAD and Topo IIα act in independent pathways in E/X extracts, but both are modulated by caspases. Several other proteins that appear to induce apoptotic chromatin condensation in nuclei have been identified. These include the mitochondrial flavoprotein AIF (apoptosis-inducing factor) [13] , L-DNase II [14] and Acinus [15] . The experiments reported here suggest that, in the absence of caspases, none of these activities is sufficient to induce apoptotic chromatin condensation unless either CAD or Topo IIα is also present and functional.
Brief Communication 925 Although a role for Topo IIα in apoptotic execution has been controversial [16, 17] , its involvement in generating high-molecular-weight DNA fragments following oxidative stress has recently been demonstrated [18] . In addition, Topo IIα has been shown to stimulate the activity of CAD against a naked DNA substrate approximately eightfold, although the cleavage of chromatin was essentially unaffected [19] . The direct interaction between Topo IIα and CAD we show here might result in targeting of CAD to sites occupied by Topo IIα at the base of chromosomal loop domains. At those sites, CAD might initially stimulate Topo IIα activity and then subsequently, upon cleavage of ICAD-L by caspases, it might commence the wholesale digestion of DNA characteristic of apoptosis, possibly being further stimulated by interactions with Topo IIα. Our results predict that CAD cleavage might initiate at or near Topo IIα-binding sites.
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Supplementary materials and methods

Preparation of apoptotic extracts and in vitro apoptosis reaction
Apoptotic (E/X) extracts [S1] were prepared from chicken DU249 cells treated for 12 h with 0.5 µM staurosporine (Sigma). Cells were washed in KPM buffer (50 mM PIPES-KOH pH 7.0, 50 mM KCl, 10 mM EGTA, 2 mM MgCl 2 , 20 mM cytochalasin B (Sigma), 1 mM DTT, 0.1 mM PMSF, 1 µg/ml each of chymostatin, leupeptin, antipain, pepstatin A) [S2] , subjected to several cycles of freezing and thawing and further disrupted by mild sonication. The cell lysate was then centrifuged at 139,000g for 2 h, yielding clear cytosolic extracts with a protein concentration of 20-30 mg/ml (measured by the Bradford assay [3] ).
HeLa nuclei (10 6 per incubation) were preincubated for 30 min at 37°C with either the Topo IIα inhibitors ICRF-159, ICRF-187 (50 µg/ml, both gifts of A. Imondi, Pharmacia) or etoposide (VP-16, 100 µM, Sigma), or the Topo I inhibitor camptothecin (0.1, 1 or 10 µM, Calbiochem), or diluent. For CAD inhibition, E/X extracts were preincubated with ICAD-L or CAD buffer (10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM DTT) for 15 min at 37°C. For caspase inhibition, E/X extracts were preincubated with DEVD-fmk (100 µM, Calbiochem) or diluent for 15 min at 37°C. Nuclei were then added (up to 10 6 nuclei per 20 µl of extract) and incubated at 37°C for up to 6 h in the presence of an ATP regeneration system [S2] . In certain experiments, 1 or 1.5 µg of purified human Topo IIα expressed in Saccharomyces cerevisiae [S4,S5] was added to the incubation. This corresponds to 2.9 pmol dimer, a ~3× physiological level of 1.7 × 10 6 molecules per nucleus [S6] . Nuclei were subsequently stained with DAPI to observe chromatin condensation, solubilized in SDS-sample buffer for protein analysis, or lysed for analysis of DNA ladder formation.
Construction of clones
For construction of intein-ICAD, mouse full-length ICAD-L [S7] (gift of S. Nagata, Osaka) was cloned into the NcoI/SmaI cloning sites of pTYB4 (New England BioLabs Inc.). GST-CAD was prepared by cloning fulllength murine CAD into the pGEX 4T-1 (Pharmacia Biotech) EcoRI and XhoI cloning site. To make the plasmid encoding the GST-CAD His 6 -tagged ICAD combination (GST-CAD/His-ICAD), His-ICAD in pRSETB [S1] was obtained by PCR with primer (5′-TGAGACGTC-TAATACGACTCAC-3′) and primer (5′-GTCGACGTCAGCAAAAAAC-CCC-3′) and cloned into the AatII site of pGEX 4T-1 containing GST-CAD.
To make the Zeo-His-HA vector, first a His tag was constructed by ligation of oligonucleotides (5′-CTAGCATGCATCATCATCATCATCAC-CGCGGA-3′) and (5′-AGCTTCCGCGGTGATGATGATGATGATG-CATG-3′). The resulting fragment was ligated into vector pZeoSV2+ (Invitrogen) that had been digested with NheI and HindIII. The HA tag in
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Figure S1
The kinetoplast minicircle decatenation assay. 
